Dermoscopic signs as predictors of non-response to imiquimod treatment in superficial basal cell carcinoma
DOI:
https://doi.org/10.23938/ASSN.0722Keywords:
Superficial basal cell carcinoma. Imiquimod. Dermoscopy. Dermatology.Abstract
Background. To describe the dermoscopic features in superficial basal cell carcinoma that are associated with a poor therapeutic response to imiquimod treatment.
Method. Clinical and dermatoscopic photographs of 56 superficial basal cell carcinomas of different patients were compared retrospectively, assessed in our office for five years and treated with topic 5% imiquimod five days a week for six weeks. The different dermatoscopic signs of the lesions were identified and the association of each of them with the response to treatment was assessed.
Results. A total response to treatment was achieved by 69.5% of the lesions of patients treated with imiquimod. Dermatoscopy of responding lesions showed a higher frequency of lesions with in focus gray dots (43.6%) and multiple erosions of less than 2 mm (61.5%), without observing statistically significant differences. Within the group with poor response to treatment, a greater number of lesions were found with the presence of arborizing telangiectasias (58.8%), blue-gray ovoid nests (41.1%), ulceration (58.8%), shiny white-red structureless areas (82.2%) and chrysalis (41.2%). The areas in blue-white veil areas (23.5%) and rainbow pattern (23.5%) were only observed in non-responding lesions. Both groups were similar regarding age, sex, diameter of lesions and frequency of some dermatoscopic signs: fine short telangiectasias, gray blue globules, arc-leaf areas and cart-wheel structures.
Conclusion. The study identified dermatoscopic criteria that are significantly associated with a worse response to treatment with imiquimod. In contrast, we found no dermatoscopic signs that correlate specifically to a complete response to treatmentDownloads
References
SEKULIC A, MIGDEN MR, ORO AE, DIRIX L, EWIS KD, HAINSWORTH JD et al. Efficacy amd safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-2179. https://doi.org/10.1056/nejmoa1113713
TEJERA A, DESCALZO MA, OTERO MM, POSADA C, RODRÍGUEZ-PAZOS L, PASTUSHENKO I et al. Skin cancer incidence and mortality in Spain: a systematic review and meta-analysis. Actas Dermosifiliogr 2016; 4: 318-328. https://doi.org/10.1016/j.adengl.2016.02.015
PERIS K, CAMPIONE E, MICANTONIO T, MARULLI G, FARGNOLI M, CHIMENTIET S. Imiquimod treatment of superficiald nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005; 31: 318-–323. https://doi.org/10.1097/00042728-200503000-00012
BEUTNER KR, GEISSE JK, HELMAN D, FOX TL, GINKELD A, OWENS ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-1007. https://doi.org/10.1016/s0190-9622(99)70261-6
MARKS R, GEBAUER K, SHUMACK S, AMIES M, BRYDEN J, FOX TL et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicentre 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-813. https://doi.org/10.1067/mjd.2001.113689
SHUMACK S, ROBINSON J, KOSSARD S, GOLITZ L, GREENWAY H, SCHROETER A et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Comparison of dosing regimens. Arch Dermatol 2002; 138: 1165-1171. https://doi.org/10.1001/archderm.138.9.1165
FALAGAS ME, ANGELOUSI AG, PEPPAS G. Imiquimod in the treatment of actinic keratosis. A meta-analysis of randomized controlled trials. J Am Acad Dermatol 2006; 55: 537-538. https://doi.org/10.1016/j.jaad.2006.05.030
LALLAS A, APALLA Z, ARGENZIANO G, LONGO C, MOSCARELLA E, SPECCHIO F et al. The dermatoscopic universe of basal cell carcinoma. Dermatol Pract Concept 2014; 11-24. https://doi.org/10.5826/dpc.0403a02
BATH-HEXTALL F, OZOLINS M, ARMSTRONG SJ, COLVER GB, PERKINS W, MILLER PS et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 2014; 96-105. https://doi.org/10.1016/s1470-2045(13)70530-8
ARITS AH, MOSTERD K, ESSERS BA, SPPORENBERG E, SOMMER A, DE ROOIJ et al. Photodinamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14: 647-654. https://doi.org/10.3410/f.718016210.793479146
URECH M, KYRGIDIS A, ARGENZIANO G, REGGIANI C, MOSCARELLA E, LONGO C et al. Dermatoscopic ulceration is a predictor of basal cell carcinoma response to Imiquimod: a retrospective study. Acta Derm Venereol 2017; 97: 117-119. https://doi.org/10.2340/00015555-2464
MCKAY KM, SAMBRANO BL, FOX PS, BASSET RL, CHON S, PRIETO VG. Thickness of superficial basal cell carcinoma predicts imiquimod efficacy, a proposal for thickness-based definition of superficial basal cell carcinoma. Br J Dermatol 2013; 169: 549-554. https://doi.org/10.1111/bjd.12402
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
